Results 221 to 230 of about 79,213 (303)

The FOXQ1/SSBP2 Regulatory Axis Drives Malignant Progression of Melanoma

open access: yesMolecular Carcinogenesis, Volume 65, Issue 11, Page 1459-1477, November 2026.
ABSTRACT Melanoma is a highly aggressive skin cancer with poor prognosis, often linked to excessive UV exposure. Despite advancements in immunotherapy and targeted treatments, melanoma's invasiveness and metastatic potential remain significant challenges.
Xiaoyu Zhang   +4 more
wiley   +1 more source

A Cilia–Centered Nicotinamide Adenine Dinucleotide (NAD+) Signaling Network Regulates Hypothalamic Lysosomal Homeostasis and Metabolic Aging

open access: yesAging Cell, Volume 25, Issue 11, November 2026.
Aging‐associated NAD+ depletion in hypothalamic neurons shortens primary cilia and disrupts CHMP4B trafficking to lysosomes during lysosomal stress, leading to impaired TRPML1–mediated Ca2+ signaling and lysosomal stress responses. Calorie restriction restores hypothalamic NAD+ levels, ciliary structure, and lysosomal homeostasis, thereby improving ...
Se Eun Park   +15 more
wiley   +1 more source

Distal cholangiocarcinoma arising in a Choi Type I septate common bile duct: a case report. [PDF]

open access: yesJ Surg Case Rep
Thorat S   +5 more
europepmc   +1 more source

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 9, Page 1288-1297, November 2026.
Among 200 patients with primary sclerosing cholangitis, 38% reported moderate to severe pruritus in the past 6 months. During 6 months of follow up, pruritus severity fluctuated significantly. Pruritus severity was linked to worse colitis activity and lower quality of life.
Richard Dean   +16 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy